CClinicalTrials.gg
RecruitingNCT07013578Updated Sep 29, 2026

TIDHI Mental Health in IBD Patients Study

An interventional study of Healing Circuits™ sessions and self-directed Healing Circuits™ curriculum in Crohn Disease (CD), Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD), sponsored by TIDHI Innovation Inc.. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by TIDHI Innovation Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to test the impact of Healing Circuits™; a structured mental health support model on IBD patients. The eligible study participants will be randomly divided into two groups: 1. the group receiving structured mental health support with a social worker and 2. the group receiving structured mental health support via a self-directed online curriculum. Both groups will be receiving the same type of therapy, Healing Circuits™, but the group receiving the therapy via the online self-directed curriculum will be receiving the therapy mostly by web-based video instruction. The two groups will be evaluated over a period of 12 months.

02

Conditions studied

  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)
  • Inflammatory Bowel Disease (IBD)

Keywords

  • Healing Circuits
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Subjects must meet each of the following criteria for enrolment into the study:

  1. Written informed consent must be obtained and documented.
  2. Males and females between the ages of 18 and 75 years of age with documented diagnosis of IBD.
  3. GAD7 and/or PHQ9 score of 10 - 15.
  4. Ability of subject to participate fully in all aspects of this clinical trial.
  5. IBD patients who plan to have ongoing medical care at TIDHI.

Exclusion criteria

Exclusion Criteria:

Subjects who exhibit any of the following conditions are to be excluded from the study:

  1. Plan for change in systemically delivered IBD-related medical therapy in the 3 months after screening.
  2. Serious underlying psychiatric disorder such as schizophrenia or bipolar disorder.
  3. Planned change in psychiatric medication, if any is being taken, within 3 months after screening.
  4. History of illegal drug abuse (excluding marijuana) or alcohol abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Sessions with a social worker based on Healing Circuits™ Methodology

    Behavioral: Healing Circuits™ sessions

  • Experimental
    Online modules of a self-directed Healing Circuits™ curriculum

    Behavioral: self-directed Healing Circuits™ curriculum

Interventions

  • BehavioralHealing Circuits™ sessions

    Treatment of the Study group will involve 12-weekly 50-minute sessions with a social worker who has been trained in the Healing Circuits™ Methodology - a structured mental health support delivered by a therapist in a one-on-one model.

  • Behavioralself-directed Healing Circuits™ curriculum

    Treatment of the Control group will involve 12 weekly online modules of a self-directed Healing Circuits™ curriculum - structured mental health support being delivered in an web-based video instruction model.

05

What researchers measure

Primary outcomes

  1. Change in Generalized Anxiety Disorder 7-item Scale (GAD-7) Score

    The Generalized Anxiety Disorder Assessment (GAD7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Scores range from 0 to 21, with higher scores indicating greater anxiety. This outcome will compare the mean change in GAD-7 scores from baseline between participants receiving one-on-one therapy and those receiving app-based therapy.

    Time frame: 3 months following initiation of Healing Circuits™

  2. Time to Improvement in Generalized Anxiety Disorder 7-item Scale (GAD-7) Score

    Improvement is defined as a ≥2-point reduction from baseline in GAD-7 score. The outcome will compare the time (months ) it takes participants in the one-on-one therapy group and the app-based therapy group to reach this level of improvement.

    Time frame: 3 months following initiation of Healing Circuits™

  3. Change in Patient Health Questionnaire-9 (PHQ-9) Score

    PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores range from 0 to 27, with higher scores indicating greater depression severity. This outcome will assess the mean difference in PHQ-9 scores between the one-on-one therapy and app-based therapy groups.

    Time frame: 3 months following initiation of Healing Circuits™

  4. Time to Improvement in Patient Health Questionnaire-9 (PHQ-9) Score

    Improvement is defined as a ≥2-point reduction from baseline in PHQ-9 score. This outcome compares the time (months ) it takes for participants in the one-on-one therapy group and the app-based therapy group to reach the improvement threshold.

    Time frame: 3 months following initiation of Healing Circuits™

Secondary outcomes

  1. Proportion of Participants Achieving at Least a 2-Point Reduction in GAD-7 Score

    This outcome measures the proportion of participants who experience a reduction of at least 2 points in the GAD-7 (range: 0-21, higher scores = worse anxiety) at 6, 9, and 12 months after beginning the Healing Circuits™ intervention.

    Time frame: 6, 9, and 12 months following initiation of Healing Circuits™

  2. Proportion of Participants Achieving at Least a 2-Point Reduction in PHQ-9 Score

    6, 9, and 12 months following initiation of Healing Circuits™

    Time frame: This outcome measures the proportion of participants who experience a reduction of at least 2 points in the PHQ-9 (range: 0-27, higher scores = worse depression) at 6, 9, and 12 months after beginning the Healing Circuits™ intervention.

  3. Mean Change in 36-Item Short Form Survey (SF-36) Score Between Groups

    This outcome measures the mean difference in scores on the SF-36, a 36-item, patient-reported survey of patient health. Each item is scored out of 100 and a higher score is correlated to more favorable health. It addresses 8 health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. The comparison will be made between the one-on-one therapy group and the app-based therapy group at the specified time points.

    Time frame: 3, 6, 9, and 12 months following initiation of Healing Circuits™

  4. Mean Change in Patient Satisfaction Score on a Likert Scale Between Groups

    This outcome measures the mean difference in patient satisfaction between the one-on-one therapy group and the app-based therapy group. Satisfaction is assessed using a custom 10-point Likert scale ranging from 1 (Worst Possible Experience) to 10 (Best Possible Experience), with higher scores indicating greater satisfaction.

    Time frame: 3, 6, 9, and 12 months following initiation of Healing Circuits™

06

Study locations

1 of 1 sites recruiting
  • Toronto Immune and Digestive Health Institute
    North York, Ontario M6A 3B4, Canada
    Recruiting
07

Registry details

Key details

Study ID
NCT07013578
Lead sponsor
TIDHI Innovation Inc.
Collaborators
Amgen, Celltrion
Responsible party
Sponsor
First posted
Jun 10, 2025
Start date
Jul 22, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Ajani Jeyakumar, HBSc BScN RN
Contact
ajeyakumar@tidhi.ca
647-812-2113
Mark Silverberg, MD, PhD
principal investigator · TIDHI Innovation Inc.
Marci Reiss, DSW
principal investigator · TIDHI Innovation Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion